[他莫昔芬治疗晚期化疗耐药卵巢癌患者的疗效与毒性评估]
[Evaluation of efficacy and toxicity of tamoxifen in patients with advanced chemotherapy resistant ovarian cancer].
作者信息
Rolski J, Pawlicki M
机构信息
Kliniki Chemioterapii Centrum Onkologii, Oddział w Krakowie.
出版信息
Ginekol Pol. 1998 Jul;69(7):586-9.
PMID:9810419
Abstract
47 patients with advanced ovarian cancer after routine treatment were treated with tamoxifen. Objective response rate (CR + PR) was 6.4%. 46.8% patients had stable disease with median time of stabilisation 6.9 m. Because of low toxicity and non satisfactory results of second line chemotherapy tamoxifen seems to be a useful treatment for this group of patients.
摘要
47例晚期卵巢癌患者在接受常规治疗后使用他莫昔芬进行治疗。客观缓解率（完全缓解+部分缓解）为6.4%。46.8%的患者病情稳定，稳定的中位时间为6.9个月。由于二线化疗毒性低且效果不理想，他莫昔芬似乎是这类患者的一种有效治疗方法。
Zotero 插件